2 results
Approved WMOCompleted
To assess the bioequivalence of two marketed formulations of ribavirin (ribavirin solution and capsules).
Approved WMOPending
To establish the preferred treatment of AIN to prevent the development of severe anal neoplasia (persistent AIN III or anal carcinoma) in HIV+ MSM and HIV+ woman.